I deeply appreciate the ability to listen to my own playlists on ladder. Like love Apple Fitness Plus, love Pelaton, but sometimes I'm like your guys' music taste and mine. Yeah.The the music side was almost an accidental discovery. So when we launched the app in 2020, we had very little money. We couldn't go invest in content that was owned. We couldn't purchase licenses. We just didn't have any resources.we launched just having no other option but giving the option of an integration with Spotify and Apple ...

Core Insights - Oceaneering International, Inc. (OII) has secured a $33,134,365 firm-fixed-price IDIQ contract from the U.S. Navy for critical infrastructure and mission-specific equipment for Virginia-class submarines [1][2][18] - The contract reflects OII's engineering capabilities and its long-standing relationship with the Department of Defense, highlighting ongoing U.S. investment in naval modernization [2][19] Contract Details - The contract includes the production and delivery of specialized components such as sail racetracks, payload tube loading platforms, and AUR canister support equipment [3][4][12] - All production and logistics operations will occur in Chesapeake, VA, with completion scheduled by June 2030, ensuring a sustained collaboration with the U.S. Navy [5][6][18] Financial Aspects - Initial funding of $2,085,151 from Fiscal Year 2025 Other Procurement (Navy) funds has been allocated to initiate the project, ensuring financial stability throughout the multi-year production timeline [7][8] Competitive Procurement Process - The contract was awarded through a competitive procurement process, with OII emerging as the leading bidder among five competitors, reinforcing its status as a preferred partner of the Navy [9][10] Implications for Naval Capabilities - The Virginia-class submarine fleet represents advanced U.S. Navy undersea warfare capabilities, and the components supplied will enhance operational versatility and combat readiness [11][12][13] - The new support structures will improve logistics, handling safety, and maintenance turnaround time, maximizing mission availability [13] Economic Impact - The execution of this contract in Chesapeake is expected to drive economic growth, creating jobs in various disciplines and stimulating local suppliers and service providers [16][17]

Company Overview - CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients [3] - The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies [3] Upcoming Event - Management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York on May 20, 2025, at 11:30 am ET [1] - Interested parties can access the live audio webcast from the Investor Relations section of the company's website, with a replay available for approximately 90 days post-event [2]

Group 1: Fellowship Announcement - The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) and CG Oncology announced the recipients of the first annual CG-SUO-CTC NMIBC Research Fellowship aimed at supporting clinical cancer research in Non-Muscle Invasive Bladder Cancer (NMIBC) [1] - The fellowship recipients, Drs. Saum Ghodoussipour and Taylor Goodstein, were recognized for their innovative research plans that have the potential to advance urology research [1] Group 2: Bladder Cancer Statistics - In 2025, it is estimated that over 84,000 individuals will be diagnosed with bladder cancer, with NMIBC accounting for approximately 75% of these cases [2] - Bladder cancer ranks as the sixth most common cancer in the United States, with men representing three-quarters of newly diagnosed cases [2] Group 3: About SUO-CTC - SUO-CTC is a clinical research network comprising over 600 members from more than 300 clinical sites across the U.S. and Canada, dedicated to advancing urology research [3] - The organization operates as a registered 501c3 not-for-profit corporation and collaborates with the Society of Urologic Oncology (SUO) [3] Group 4: About CG Oncology - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing therapies for bladder cancer patients [4] - The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies [4] Group 5: Research Focus of Fellowship Recipients - Dr. Saum Ghodoussipour's research focuses on dynamic intra-tumor heterogeneity in NMIBC [5] - Dr. Taylor Goodstein's research involves spatial transcriptomic profiling of the tumor microenvironment in BCG-unresponsive NMIBC patients treated with novel intravesical gene therapies [5]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed along ...